Natera said its Signatera minimal residual disease (MRD) test platform received certification under the EU In Vitro Diagnostic Regulation (IVDR) for multiple cancers. The platform review included assessment of analytical and clinical validity for the assay, specimen collection kit, and associated software. IVDR certification strengthens the regulatory standing of MRD testing as a decision-support tool for oncology care, particularly in settings where MRD status is used to guide therapy intensity or monitor disease recurrence. For developers and clinicians, the milestone supports broader EU adoption of tumor-informed MRD assays that rely on personalized genomic targets rather than tumor-agnostic biomarkers.